Literature DB >> 11739164

Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors.

S Indraccolo1, S Minuzzo, F Roccaforte, R Zamarchi, W Habeler, L Stievano, V Tosello, D Klein, W H Günzburg, G Basso, L Chieco-Bianchi, A Amadori.   

Abstract

Locus control region (LCR) sequences are involved in the establishment of open chromosomal domains. To evaluate the possibility of exploiting the human CD2 LCR to regulate gene expression by Moloney murine leukemia virus (Mo-MLV)-based retroviral vectors in T cells, it was included in vectors carrying the enhanced green fluorescence protein (EGFP) reporter gene; then transduction in vitro of lymphoid and nonlymphoid cell lines was performed. Deletion of the viral enhancer in the Mo-MLV long terminal repeat was necessary to detect LCR activity in the context of these retroviral vectors. It was found that a full-length (2.1 kb), but not a truncated (1.0 kb), CD2 LCR retained the ability to modulate reporter gene expression by Mo-MLV-derived retroviral vectors, leading to a homogeneous, unimodal pattern of EGFP expression that remained unmodified in culture over time, specifically in T-cell lines; on the other hand, viral titer was strongly reduced compared with vectors not carrying the LCR. Lentiviral vectors containing the CD2 LCR could be generated at higher titers and were used to analyze its effects on gene expression in primary T cells. Subcutaneous implantation of genetically modified cells in immunodeficient mice showed that retroviral vectors carrying the CD2 LCR conferred an advantage in terms of transgene expression in vivo, compared with the parental vector, by preventing the down-modulation of EGFP expression. These findings suggest a potential application of this LCR to increase gene expression by retroviral and lentiviral vectors in T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739164     DOI: 10.1182/blood.v98.13.3607

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction.

Authors:  Vincent Hurez; Robin D Hautton; James Oliver; R James Matthews; Casey K Weaver
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Lentivirus vectors incorporating the immunoglobulin heavy chain enhancer and matrix attachment regions provide position-independent expression in B lymphocytes.

Authors:  Carolyn Lutzko; Dinithi Senadheera; Dianne Skelton; Denise Petersen; Donald B Kohn
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

3.  Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders.

Authors:  Blythe D Sather; Byoung Y Ryu; Brigid V Stirling; Mikhail Garibov; Hannah M Kerns; Stéphanie Humblet-Baron; Alexander Astrakhan; David J Rawlings
Journal:  Mol Ther       Date:  2010-12-07       Impact factor: 11.454

4.  Development of lentiviral vectors with regulated respiratory epithelial expression in vivo.

Authors:  Benjamin Hendrickson; Dinithi Senadheera; Suparna Mishra; Kim Chi T Bui; Xingchao Wang; Belinda Chan; Denise Petersen; Karen Pepper; Carolyn Lutzko
Journal:  Am J Respir Cell Mol Biol       Date:  2007-06-15       Impact factor: 6.914

Review 5.  Lentiviral vectors for immune cells targeting.

Authors:  Steven Froelich; April Tai; Pin Wang
Journal:  Immunopharmacol Immunotoxicol       Date:  2010-06       Impact factor: 2.730

6.  Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells.

Authors:  Fang Zhang; Susannah I Thornhill; Steven J Howe; Meera Ulaganathan; Axel Schambach; Joanna Sinclair; Christine Kinnon; H Bobby Gaspar; Michael Antoniou; Adrian J Thrasher
Journal:  Blood       Date:  2007-04-24       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.